Trapping the Machines that Drive Cancer
We are a clinical-stage biotechnology company developing next-generation small-molecule cancer therapies by targeting the activated state of enzymes. Our proprietary ALLOS platform leverages AI-guided molecular approaches to target genetically defined cancer vulnerabilities.
Redefining what’s needed in oncology – and how we get there
The Challenge
Cancer therapies are often limited by a "toxicity barrier”. Drugs that attack cancer cells can also harm healthy tissue, leading to severe side effects. At the same time, tumors evolve resistance, limiting the durability of patients' responses. This reflects a limitation of conventional inhibitor drugs, rather than of the underlying cancer biology.
Hitting the Achilles' Heel
At Eisbach, we harness the power of "synthetic lethality” – targeting genetic vulnerabilities unique to cancer cells. By disabling the activated state of the molecular machinery tumors depend on, we trigger cancer cell death while sparing healthy tissue.
Allos Platform
01 Real Biology First
Most cancer drugs are small-molecule inhibitors discovered using simplified assays that remove targets from their natural regulation.
This creates a gap between what appears promising in the lab and what ultimately works for patients.
To build better cancer medicines, drug discovery must begin with biological regulation as it exists in vivo.
02 Screening Beyond the Tube
Eisbach conducts wet-lab and computational screens on full-length enzyme complexes in their physiologically activated state.
By including natural allosteric activators, we observe how targets behave within complex biological systems rather than in isolation.
This allows us to hit unique molecular vulnerabilities and develop drugs that trap our targets, something conventional platforms miss.
03 Intelligence Built on Biology
Using data generated from these physiological assays, we train proprietary target-specific LLMs. These models learn the molecular logic of each target and predict novel compounds with unprecedented properties, including compounds that enable selective target trapping.
The resulting drug candidates are highly selective by design and hit cancer-specific molecular vulnerabilities.
The outcome is a new class of therapies that are gentle on the patient and decisive against tumors.
Approach
Pioneering Discovery
Advanced in-house AI
Eisbach's Next Gen Safe Oncology Drugs
The ALLOS platform
Targeted Clinical Development
The value of our approach
Targeted Precision
We pioneer a new class of precision oncology by targeting regulatory control mechanisms rather than simply inhibiting catalytic activity.
By trapping the activated state of our targets, we achieve superior biological precision, reduced off-target activity, and highly differentiated IP.
Durable Impact
ALLOS is a scalable discovery engine building a repeatable pipeline of first-in-class allosteric therapies for genetically defined cancer dependencies.
Our proprietary AI models accelerate this process, using platform-generated datasets to compound learning, enabling the persistent disruption of cancer-driving mechanisms.
Clinical Confidence
We evaluate targets in their physiological context, closely reflecting real tumor biology and prioritizing molecules likely to benefit patients.
Our Phase 1/2 ALC1 program is establishing clinical proof-of-mechanism in HRD tumors, with early evidence supporting target engagement and tolerability in patients.
Synergistic Safety
ALLOS is engineered to produce efficacious and selective drugs with reduced toxicity, widening the therapeutic window and enabling combination with established therapies.
By exploring combinations with PARP inhibitors, we are reaching a key value inflection point.
Targeting Tumor-Specific DNA Repair Dependencies
Targets
ALC1 (CHD1L) is a PARP-activated chromatin remodeler that opens chromatin at sites of DNA damage, enabling repair proteins to access damaged DNA.
Dependency on ALC1 is observed in tumors with homologous recombination deficiency (HRD), including subsets of breast and ovarian cancers. In these genetically defined tumors, cancer cells rely on ALC1-mediated chromatin remodeling to survive elevated DNA damage and replication stress.
Inhibiting ALC1 creates a synthetic-lethal vulnerability in HRD cancers by removing a key compensatory repair mechanism. Targeting ALC1 may therefore help overcome resistance to PARP inhibitors and enable rational combination strategies in clearly defined patient populations.
Our ALC1 program is currently in Phase 1/2 clinical trials with our lead candidate, EIS-12656.
CHD1 is a chromatin remodeler that regulates gene expression, DNA repair, and chromatin organization. By controlling access to DNA, CHD1 helps maintain genome stability and influences cellular transcriptional programs.
Dependency on CHD1 has been observed in tumors with PTEN loss, a common genetic alteration in several cancers, including prostate cancer. In these genetically defined tumors, cancer cells rely on CHD1-mediated chromatin regulation to support tumor growth and survival.
This synthetic-lethal vulnerability is being exploited to develop first-in-class small-molecule drugs using our AI-powered ALLOS platform. The CHD1 program is currently in the lead optimization phase.
WRN is a RecQ helicase that supports faithful genome duplication and protects cells from replication stress, playing an essential role in maintaining genome stability.
Dependency on WRN has been observed in tumors with microsatellite instability-high (MSI-high) status, a genetically defined subset of cancers including colorectal, endometrial, and gastric tumors.
Currently in late preclinical development, Eisbach is developing small-molecule WRN drugs to exploit this vulnerability and enable selective, precision oncology therapies for MSI-high cancers.
Beyond our disclosed targets, Eisbach is actively developing small molecules targeting additional high-value molecular machines that play critical roles in tumor genome stability using our proprietary ALLOS platform, extending our trapping-based approach across additional cancer indications.
We are currently advancing two undisclosed discovery programs within solid tumor oncology, reflecting the breadth and potential of our unique drug discovery capabilities.
Eisbach welcomes scientific exchange and business development discussions to explore strategic partnerships that will accelerate the clinical development of disruptive and sustainable targeted therapies.
Pipeline
Eisbach’s pipeline of allosteric therapies targets molecular machines that reorganize the cancer genome.
Discovery
Lead Op
IND
Phase I
Phase II
Biomarker setting
Program
Chromatin remodeling helicases
HRD
ALC1
EIS-12656 (2+ backup series)
with Tim Yap @ MDACC
PTEN
CHD1
DNA-dependent helicases
MSI
WRN
Strategic, multi-target collaboration @ MDACC
HRD
X
Multiple Programs
Join us in advancing first-in-class cancer therapies
Our Funding Partners
Our work is supported by a network of committed funding partners who share our vision of advancing precision oncology. Their support enables us to translate cutting-edge science into clinical programs, accelerate drug development, and bring innovative therapies closer to patients who need them.
